Enliven Therapeutics files Form 144 to sell 25,000

Enliven Therapeutics submitted a Form 144 disclosing a proposed sale of 25,000 shares of Common Stock through Jefferies LLC, with an aggregate value listed as $914,750 and an entry date of 03/31/2026 on Nasdaq.

Rhea-AI Filing Summary

Enliven Therapeutics submitted a Form 144 disclosing a proposed sale of 25,000 shares of Common Stock through Jefferies LLC, with an aggregate value listed as $914,750 and an entry date of 03/31/2026 on Nasdaq.

The filing also lists recent sales by Joseph Lyssikatos: 41,302 shares on 01/08/2026 for $993,437.48 and 91,198 shares on 01/09/2026 for $2,482,579.19, plus several other dispositions in January–February 2026.

Insights

Securities Compliance Analyst

Form 144 reports proposed resale of restricted/control securities and recent insider dispositions.

The filing lists a proposed transaction of $914,750 tied to 25,000 common shares to be sold through Jefferies LLC with an entry date of 03/31/2026. Form 144 is a notice of proposed sale under Rule 144 and does not by itself confirm completion of any trade.

Multiple prior sales by Joseph Lyssikatos are listed with dates and gross proceeds; these are reported dispositions and may reflect staged liquidity rather than a single event. Timing and execution details for the 25,000-share notice are not provided in the excerpt.

Key Figures

Proposed shares to be sold: 25,000 shares Aggregate value listed: $914,750 Sale example — 01/08/2026: 41,302 shares / $993,437.48 +2 more

5 metrics

Proposed shares to be sold 25,000 shares Listed with Jefferies LLC entry dated 03/31/2026

Aggregate value listed $914,750 Associated with the 25,000-share entry on 03/31/2026

Sale example — 01/08/2026 41,302 shares / $993,437.48 Disposition by Joseph Lyssikatos on 01/08/2026

Sale example — 01/09/2026 91,198 shares / $2,482,579.19 Disposition by Joseph Lyssikatos on 01/09/2026

Additional dispositions (Jan–Feb 2026) 20,000; 5,000; 50,000; 20,000; 5,000 shares Multiple sales by Joseph Lyssikatos between 01/20/2026 and 02/25/2026 with listed proceeds

Key Terms

Form 144, Founder Shares, Jefferies LLC

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Founder Shares financial

"Founder Shares | Enliven Therapeutics"

Founder shares are the ownership stakes given to the people who start a company, often with extra voting power or protections compared with ordinary shares. For investors, they matter because founders’ control and incentives influence decisions about strategy, hiring, and whether the company sells or stays independent — like a family that keeps majority voting rights in a household decision. High founder ownership can mean stable leadership but also a risk that outside shareholders have less influence.

Jefferies LLC other

"Common | Jefferies LLC 520 Madison Ave"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Enliven Therapeutics' Form 144 for ELVN mean?

It notifies the SEC of a proposed resale of 25,000 common shares through Jefferies LLC. The filing lists an aggregate value of $914,750 and an entry date of 03/31/2026, but does not confirm execution.

Who sold shares recently according to the ELVN filing?

The filing lists multiple dispositions by Joseph Lyssikatos, including 41,302 shares on 01/08/2026 for $993,437.48 and 91,198 shares on 01/09/2026 for $2,482,579.19, plus other January–February 2026 sales.

Does a Form 144 guarantee shares were sold for ELVN?

No. A Form 144 is a notice of intent to sell restricted or control securities under Rule 144. It does not certify that the sale occurred; execution and settlement details are separate and not shown here.

What market venue is indicated for the proposed ELVN sale?

The excerpt lists Nasdaq as the market and identifies Jefferies LLC as the broker-dealer associated with the 25,000 share entry dated 03/31/2026 and an aggregate value of $914,750.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 04:29 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001967150
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Lyssikatos Joseph P
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	25000	914750.00	59000000	03/31/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder Shares	Enliven Therapeutics			25000	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	01/08/2026	41302	993437.48
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	01/09/2026	91198	2482579.19
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	01/20/2026	20000	535099.00
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/06/2026	5000	145219.10
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/18/2026	50000	1317640.00
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/19/2026	20000	520217.41
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	02/25/2026	5000	144613.70

144: Remarks and Signature

Remarks	All sales are to be made pursuant to a previously signed/adopted 10b5-1 selling plan dated 12/30/2025, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold from The Lyssikatos Revocable Trust UAD 12/15/11.
Date of Notice	03/31/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/30/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Joseph Lyssikatos
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)